MK-4280A, TRIFLURIDINE, COMBINATIONS, REGORAFENIB
MK-4280A-007
Phase 3 small_molecule active
Quick answer
MK-4280A, TRIFLURIDINE, COMBINATIONS, REGORAFENIB for Colorectal Cancer is a Phase 3 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck Sharp and Dohme
- Indication
- Colorectal Cancer
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active